Halozyme Therapeutics Inc

Halozyme’s FDA approval of the DARZALEX FASPRO‑based regimen, a first for hyaluronidase‑containing products, boosts RRMM treatment and investor confidence.

Halozyme Therapeutics Q4 2025 earnings preview: analysts forecast $2.16 EPS, $435M revenue, driven by hyaluronidase drug‑delivery growth and licensing deals.

Halozyme raises 2025 revenue outlook, expands hyaluronidase platform with Surf Bio acquisition—boosting drug‑delivery prospects in diabetes, oncology, dermatology and more.

Halozyme Therapeutics’ hyaluronidase platform and expanding pipeline could push shares to a median $76 target, offering growth upside amid steady earnings and strategic licensing.

Halozyme’s new CEO equity plan and Jim Lang’s board seat boost leadership focus, drive drug‑delivery growth, and aim to unlock key partnerships and shareholder value.

Halozyme Therapeutics: analyst ratings clash as investors weigh its hyaluronidase platform, partnership pipeline, and valuation—what drives its next move?

Halozyme’s acquisition of Elektrofi expands its ultra‑high concentration drug‑delivery platform, boosting royalty revenue and speeding biologics into market.

Halozyme Therapeutics Inc. is facing market headwinds due to downgrades and concerns over pricing controls, but some analysts remain optimistic about its long-term potential.

Halozyme Therapeutics Inc’s stock price plummeted due to new Medicare policies affecting drug pricing negotiations, leading to analyst downgrades and concerns over price control risks.

Halozyme Therapeutics Inc. has seen its stock value plummet due to regulatory headwinds, including Medicare’s new pricing strategy and analyst downgrades, casting a shadow over its future growth prospects.